The Mirati Therapeutics, Inc. ticker is MRTX and is traded on the NASDAQ.
In June 2013, Mirati Therapeutics, Inc. became the ultimate parent corporation of MethylGene Inc. and subsidiaries by a court - and shareholder-approved plan of agreement. Mirati shares began trading on the NASDAQ on July 15, 2013.
3545 Cray Court San Diego, CA 92121
December 31st
Ernst & Young LLP
Cooley LLP
Computershare, Inc.
Mirati Therapeutics, Inc. does not expect to declare or pay any cash or other dividends on our common stock, as we intend to reinvest cash flow generated by operations in our business.
Mirati Therapeutics, Inc. does not have a direct stock purchase plan.
Quarterly and annual reports, as well as other SEC filings, can be accessed on the Financials & Filings portion of our Investor Relations website or directly from the SEC at http://www.sec.gov/. Note that in June 2013, Mirati Therapeutics, Inc. became the ultimate parent corporation of MethylGene Inc. and subsidiaries by a courtand shareholder-approved plan of arrangement.
You can contact Mirati Therapeutics, Inc. Investor Relations group via email at ir@mirati.com.